Figure 2.

BTA938 and zanamivir treatment for an influenza A/Victoria/3/75 (H3N2) virus infection. Mice were treated twice daily with the indicated doses of BTA938 or zanamivir for 5 days, beginning 4 h post-virus challenge. Survival (a and c) and body weight (b and d) were monitored for 21 days post-challenge. A significant difference in survival, compared with placebo, was observed for all the treatment groups (a and c). A significant difference in mean body weight was also observed for all the treatment groups (b and d). ***P < 0.001.